Found 7934 clinical trials
Improving Health and Well-being of People with Alzheimer’s Disease and Related Dementias and their Family Caregivers
Preserving the health and well-being of people with ADRD and their family caregivers is a priority for healthcare delivery and policy. However, ADRD care research has traditionally focused on physical, and functional health status7-8 or dementia-specific quality of life (QoL) as outcomes of care.8-9 These outcomes do not capture a …
- 0 views
- 07 Sep, 2023
- 1 location
- Online study
RB-ADSC for Treatment of Mild to Moderate Alzheimer's Disease
into an effective “whole brain” treatment for Alzheimer disease, with secondaryobjectives to evaluate preliminary efficacy, in order to determine a recommended phase 2
- 0 views
- 06 Sep, 2023
- 1 location
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (202200050434)
Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS <50% and KRAS G12C mutation
- 43 views
- 25 Aug, 2023
- 24 locations
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease (REASON) (REASON)
Parkinson's Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094.The study is open for PD patients with verified presence or absence of variations in
- 853 views
- 17 Jul, 2023
- 16 locations
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and other myeloid neoplasms.
- 4 views
- 28 Aug, 2023
- 21 locations
![Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type](/media/imagery/302513.svg)
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in participants with dementia of the Alzheimer's type.
- 35 views
- 12 Sep, 2023
- 41 locations
Preventing Alzheimer's With Cognitive Training (PACT)
Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging and Alzheimer's disease or another type of dementia, and …
- 9 views
- 25 Apr, 2023
- 5 locations
Study in Parkinson Disease of Exercise (SPARX3)
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax …
- 175 views
- 07 Oct, 2022
- 26 locations
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011) (Hope)
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 345 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- …
- 10 views
- 22 Aug, 2023
- 7 locations
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (Inhibikase)
This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 75 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease. This 12 week study is …
- 0 views
- 30 Sep, 2023
- 3 locations